Tianjin Chase Sun Pharmaceutical Co.,Ltd

SZSE:300026 Rapport sur les actions

Capitalisation boursière : CN¥10.2b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Tianjin Chase Sun PharmaceuticalLtd Croissance future

Future contrôle des critères 1/6

Tianjin Chase Sun PharmaceuticalLtd is forecast to grow earnings and revenue by 16.8% and 6.5% per annum respectively. EPS is expected to grow by 16.3% per annum. Return on equity is forecast to be 6% in 3 years.

Informations clés

16.8%

Taux de croissance des bénéfices

16.3%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices18.8%
Taux de croissance des recettes6.5%
Rendement futur des capitaux propres6.0%
Couverture par les analystes

Low

Dernière mise à jour17 May 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

Aug 02
These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings

Jun 12
There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03

May 22
Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03

This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts

May 21
This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts

Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 04
Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Prévisions de croissance des bénéfices et des revenus

SZSE:300026 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20267,083664N/A6291
12/31/20256,511557N/A4311
12/31/20246,194533N/A7151
3/31/20245,9133899801,309N/A
12/31/20236,1095071,1831,530N/A
9/30/20236,6726631,1121,485N/A
6/30/20236,762617382911N/A
3/31/20236,577561269928N/A
1/1/20236,650624-25745N/A
9/30/20227,084521-538262N/A
6/30/20227,496602-258497N/A
3/31/20227,764732-317418N/A
12/31/20217,671687-286392N/A
9/30/20217,266611111717N/A
6/30/20217,192667-173395N/A
3/31/20217,001657-162364N/A
12/31/20206,488573-367197N/A
9/30/20206,109485-753-148N/A
6/30/20205,497396-563100N/A
3/31/20205,085337-519149N/A
12/31/20195,003403-375216N/A
9/30/20194,796264-221247N/A
6/30/20194,548216-253147N/A
3/31/20194,303219-101225N/A
12/31/20184,22421193388N/A
9/30/20184,015463297593N/A
6/30/20183,894514529805N/A
3/31/20183,605485557865N/A
12/31/20173,374451N/A742N/A
9/30/20173,543633N/A610N/A
6/30/20173,564630N/A590N/A
3/31/20173,743666N/A472N/A
12/31/20163,867659N/A448N/A
9/30/20163,722582N/A362N/A
6/30/20163,635599N/A251N/A
3/31/20163,596572N/A108N/A
12/31/20153,348535N/A121N/A
9/30/20153,187541N/A193N/A
6/30/20153,076474N/A115N/A
3/31/20152,969452N/A220N/A
12/31/20142,864447N/A150N/A
9/30/20142,681421N/A105N/A
6/30/20142,405395N/A110N/A
3/31/20142,201362N/A93N/A
12/31/20132,097340N/A144N/A
9/30/20131,862308N/A148N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 300026's forecast earnings growth (16.8% per year) is above the savings rate (2.9%).

Bénéfices vs marché: 300026's earnings (16.8% per year) are forecast to grow slower than the CN market (21.9% per year).

Croissance élevée des bénéfices: 300026's earnings are forecast to grow, but not significantly.

Chiffre d'affaires vs marché: 300026's revenue (6.5% per year) is forecast to grow slower than the CN market (13.4% per year).

Croissance élevée des revenus: 300026's revenue (6.5% per year) is forecast to grow slower than 20% per year.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: 300026's Return on Equity is forecast to be low in 3 years time (6%).


Découvrir les entreprises en croissance